{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Cidara Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Cidara Therapeutics, Inc. is in a mildly bullish trend with strong weekly and monthly MACD signals, despite a bearish monthly RSI, having outperformed the S&P 500 over the past year with a 734.41% return, but underperformed in the last week with a -8.27% return.
Is Cidara Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Cidara Therapeutics, Inc. has a mildly bullish trend, supported by a bullish MACD and moving averages, despite a bearish monthly RSI, with a year-to-date return of 246.43% compared to the S&P 500's 15.47%.
Is Cidara Therapeutics, Inc. technically bullish or bearish?
As of September 12, 2025, Cidara Therapeutics, Inc. has a bullish trend supported by strong indicators like MACD and moving averages, despite a bearish RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 164.96%.
Cidara Therapeutics Hits New 52-Week High of $71.36, Up 430%
Cidara Therapeutics, Inc. achieved a new 52-week high of USD 71.36 on September 18, 2025, marking a 430.31% increase over the past year. With a market capitalization of USD 1,576 million, the company is noted for its innovative strategies in the Pharmaceuticals & Biotechnology industry, despite currently facing losses.
Is Cidara Therapeutics, Inc. overvalued or undervalued?
As of October 5, 2023, Cidara Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, significantly lower than peers like Myriad Genetics and Amgen, while its stock performance has outpaced the Sensex, indicating potential market undervaluation.
Is Cidara Therapeutics, Inc. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data for Cidara Therapeutics, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Cidara Therapeutics, Inc.?
As of March 2022, the management team of Cidara Therapeutics, Inc. includes Mr. Daniel Burgess (Independent Chairman), Dr. Jeffrey Stein (President and CEO), and several Independent Directors: Dr. Timothy Franson, Dr. David Gollaher, Ms. Chrysa Mineo, and Mr. Theodore Schroeder. They oversee the company's strategic direction and operations.
What does Cidara Therapeutics, Inc. do?
Cidara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new anti-infectives, with a market cap of approximately $286.63 million and a recent net profit of -$23 million. The company has no dividend yield and is currently loss-making.
How big is Cidara Therapeutics, Inc.?
As of Jun 18, Cidara Therapeutics, Inc. has a market capitalization of 286.63 million and reported net sales of 0.30 million with a net profit of -185.60 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
